Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On September 29, 2022, Moderna, Inc. (the "Company") announced that Juan Andres, the Company's Chief Technical Operations and Quality Officer, will transition into a new role as President, Strategic Partnerships and Enterprise Expansion of the Company, effective January 1, 2023. In his new role, Mr. Andres will focus on building out the Company's organization to support its growing pipeline.

The Company further announced that Dr. Jerh Collins, Ph.D., who will join the Company on October 3, 2022, will assume the role of Chief Technical Operations and Quality Officer of the Company, effective January 1, 2023. Dr. Collins joins Moderna from Novartis, where for the last nearly 30 years he had roles of increasing responsibility focused on pharmaceutical production and manufacturing, including roles serving as Head of Global Chemical Operations and Anti-Infectives and as Head of Global Chemical Operations.

Item 7.01 Regulation FD Disclosure.

On September 29, 2022, the Company issued a press release announcing the appointment of Mr. Andres to the role of President, Strategic Partnerships and Enterprise Expansion and the addition of Dr. Collins as Chief Technical Operations and Quality Officer to replace Mr. Andres. A copy of this press release is furnished as Exhibit 99.1 to this Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits.

   Exhibit
     No.             Description
    99.1               Press release by Moderna, Inc. dated September 29, 2022
     104             Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses